Cited 0 times in Scipus Cited Count

Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study

DC Field Value Language
dc.contributor.authorKim, DH-
dc.contributor.authorLim, ST-
dc.contributor.authorKim, HR-
dc.contributor.authorKang, EJ-
dc.contributor.authorAhn, HK-
dc.contributor.authorLee, YG-
dc.contributor.authorSun, S-
dc.contributor.authorKwon, JH-
dc.contributor.authorLee, SC-
dc.contributor.authorLee, HW-
dc.contributor.authorKim, MK-
dc.contributor.authorKeam, B-
dc.contributor.authorPark, KU-
dc.contributor.authorShin, SH-
dc.contributor.authorYun, HJ-
dc.date.accessioned2024-04-04T06:27:37Z-
dc.date.available2024-04-04T06:27:37Z-
dc.date.issued2024-
dc.identifier.issn1368-8375-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/32472-
dc.description.abstractObjectives: This study aimed to investigate whether genetic alterations in PI3KCA and the cell cycle pathways influence the efficacy of durvalumab, an immune checkpoint inhibitor, in patients with head and neck squamous cell carcinoma (HNSCC) who had previously failed platinum-based treatment. Materials and methods: We obtained data from a phase II umbrella trial of patients with HNSCC who failed platinum-based treatment (TRIUMPH, NCT03292250). Patients receiving durvalumab treatment comprised those with PIK3CA alterations (Group A), those with cell cycle pathway alterations such as CDKN2A (Group B), and those with no druggable genetic alterations (Group C). We analyzed the overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) in each group and evaluated the potential predictive factors for durvalumab. Results: We analyzed the data of 87 patients: 18, 12, and 57 in groups A, B, and C, respectively. The ORRs were 27.8 %, 8.3 %, and 15.8 % in Groups A, B, and C, respectively (P = 0.329), and the median PFS for each group was 2.3, 1.6, and 1.7 months, respectively, with no significant differences between the groups (P = 0.24). Notably, patients with lower neutrophil–lymphocyte ratio (NLR) (≤5.8) had longer PFS (median, 2.8 vs 1.6 months, P < 0.001), while those with lower platelet-lymphocyte ratio (PLR) (≤491.2) exhibited longer PFS (median, 1.8 vs 1.2 months, P < 0.001). Conclusion: Durvalumab's efficacy was similar, irrespective of the presence of PIK3CA or cell cycle pathway genetic alterations in patients with platinum-resistant HNSCC. The NLR and PLR may be promising predictive biomarkers.-
dc.language.isoen-
dc.titleImpact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study-
dc.typeArticle-
dc.identifier.pmid38458039-
dc.subject.keywordCell cycle pathway-
dc.subject.keywordDurvalumab-
dc.subject.keywordHead and neck squamous cell carcinoma-
dc.subject.keywordNeutrophil-lymphocyte ratio-
dc.subject.keywordPI3KCA-
dc.subject.keywordPlatelet-lymphocyte ratio-
dc.contributor.affiliatedAuthorLee, HW-
dc.type.localJournal Papers-
dc.identifier.doi10.1016/j.oraloncology.2024.106739-
dc.citation.titleOral oncology-
dc.citation.volume151-
dc.citation.date2024-
dc.citation.startPage106739-
dc.citation.endPage106739-
dc.identifier.bibliographicCitationOral oncology, 151. : 106739-106739, 2024-
dc.embargo.liftdate9999-12-31-
dc.embargo.terms9999-12-31-
dc.identifier.eissn1879-0593-
dc.relation.journalidJ013688375-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Hematology-Oncology
Files in This Item:
There are no files associated with this item.

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse